We are live on ! Find out more

956 hedge funds and large institutions have $28B invested in Biogen in 2024 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 306 increasing their positions, 356 reducing their positions, and 144 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital inflows, than outflows

Capital inflows: $2.28B | Capital outflows: $2.07B

0.37% more ownership

Funds ownership: 89.04% → 89.41% (+0.37%)

0% more call options, than puts

Call options by funds: $303M | Put options by funds: $303M

5% less funds holding

Funds holding: 1,004 → 956 (-48)

14% less repeat investments, than reductions

Existing positions increased: 306 | Existing positions reduced: 356

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

28% less first-time investments, than exits

New positions opened: 104 | Existing positions closed: 144

Holders
956
Holders Change
-48
Holders Change %
-4.78%
% of All Funds
13.72%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.13%
New
104
Increased
306
Reduced
356
Closed
144
Calls
$303​M
Puts
$303​M
Net Calls
+$554​K
Net Calls Change
-⁠$146​M

BIIB Hedge Fund Activity: Q1 2024 in Review

956 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2024, worth a combined $28B — down 16% from $33.4B a quarter earlier.

Sellers outnumbered buyers: 144 funds closed out of BIIB and 104 opened new positions — a net loss of 40 holders — while 356 trimmed existing stakes and 306 added.

The largest buyer was Vanguard Group, adding an estimated $507M. The largest seller was First Trust Advisors, cutting an estimated $151M.

  • 956 institutional investors held Biogen (BIIB) as of Q1 2024, down from 1,004 in Q4 2023.
  • Funds reported $28B of Biogen stock for Q1 2024, down 16% quarter-over-quarter.
  • 104 funds opened new Biogen positions in Q1 2024 and 144 closed out, a net change of -40 holders.
  • The largest Biogen buyer in Q1 2024 was Vanguard Group, an estimated $507M added.
  • The largest Biogen seller in Q1 2024 was First Trust Advisors, an estimated $151M sold.

Based on aggregated 13F filings for Q1 2024.